Journal
JOURNAL OF NEURAL TRANSMISSION
Volume 116, Issue 4, Pages 457-465Publisher
SPRINGER WIEN
DOI: 10.1007/s00702-009-0189-x
Keywords
Alzheimer's disease; Huperzine A; Acetylcholinesterase inhibitor; Clinical trials; Meta-analysis; Meta-regression
Categories
Funding
- National Natural Science Foundation of China [30772553]
- Program of Shanghai Subject Chief Scientist [06XD14011]
- Major Basic Research Project of Shanghai Municipal Science and Technology Commission [07DJ14005]
- Shanghai Rising-Star Program [08QA14042]
Ask authors/readers for more resources
The objective of this study was to provide an updated meta-analysis of the efficacy and safety of huperzine A (HupA) in Alzheimer's disease (AD). We searched for randomized trials comparing HupA with placebo in the treatment of AD. The primary outcome measures were mini-mental state examination (MMSE) and activities of daily living scale (ADL). Data were extracted from four randomized clinical trials and analyzed using standard meta-analysis and meta-regression methods. Oral administration of HupA for 8-24 weeks (300-500 mu g daily) led to significant improvements in MMSE and ADL. The results of meta-regression showed that the estimated effect size of MMSE and ADL was increased over the treatment time. Most adverse events were cholinergic in nature and no serious adverse events occurred. Huperzine A is a well-tolerated drug that could significantly improve cognitive performance and ADL in patients with AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available